ライフサイエンスコーパス: hypercholesterolemia

1 tic causes of dyslipidemia (such as familial hypercholesterolemia).

2 ] for hypertension, and 2.57 [2.40-2.75] for hypercholesterolemia).

3 odel of adeno-associated virus (AAV)-induced hypercholesterolemia.

4 erebrovascular disease, obesity, cachexia or hypercholesterolemia.

5 vated in individuals with FH who have severe hypercholesterolemia.

6 vate SHP might be developed for treatment of hypercholesterolemia.

7 To investigate hepatic T-cell subsets upon hypercholesterolemia.

8 ow improved management of conditions such as hypercholesterolemia.

9 mutations affect LDL metabolism and lead to hypercholesterolemia.

10 s had a score highly suggestive of polygenic hypercholesterolemia.

11 hypertension, smoking, body mass index, and hypercholesterolemia.

12 lerosis development in a context of moderate hypercholesterolemia.

13 s an FDA approved drug for treating familial hypercholesterolemia.

14 vascular disease, hypertension, diabetes, or hypercholesterolemia.

15 g hepatocyte production of apoB and treating hypercholesterolemia.

16 tanding of diseases like atherosclerosis and hypercholesterolemia.

17 benefit in patients with homozygous familial hypercholesterolemia.

18 ven though they exhibited different types of hypercholesterolemia.

19 patients with nephrotic syndrome-associated hypercholesterolemia.

20 orbidities or who have heterozygous familial hypercholesterolemia.

21 had positive screening results for familial hypercholesterolemia.

22 reased platelet activation in the setting of hypercholesterolemia.

23 litus, 17 420 of hypertension, and 24 385 of hypercholesterolemia.

24 f PCSK9 in adults with heterozygous familial hypercholesterolemia.

25 n of the APOB gene as treatment for familial hypercholesterolemia.

26 the subgroup of concurrent hypertension and hypercholesterolemia.

27 f the drug ezetimibe, which is used to treat hypercholesterolemia.

28 ic plaques in humans and in a mouse model of hypercholesterolemia.

29 ving lopinavir/ritonavir-based regimens with hypercholesterolemia.

30 lesterol levels in all genotypes of familial hypercholesterolemia.

31 atherosclerosis, but only in the setting of hypercholesterolemia.

32 available for patients with the most extreme hypercholesterolemia.

33 roved as a treatment for homozygous familial hypercholesterolemia.

34 erapeutic strategy in stroke associated with hypercholesterolemia.

35 ted with increased risks of hypertension and hypercholesterolemia.

36 ediatric patients with heterozygous familial hypercholesterolemia.

37 orders, and lipid disorders such as familial hypercholesterolemia.

38 ascular disease, obesity, undernutrition, or hypercholesterolemia.

39 commended by guidelines for the treatment of hypercholesterolemia.

40 , including steatotic liver disease and mild hypercholesterolemia.

41 , and 23-fold higher among those with severe hypercholesterolemia.

42 rare, monogenic mutation related to familial hypercholesterolemia.

43 en, smokers, with a family history of CAD or hypercholesterolemia.

44 had positive screening results for familial hypercholesterolemia (0.3% of the 10,095 children; 95% c

45 had positive screening results for familial hypercholesterolemia (0.4% of the 10,095 children, inclu

46 Z; -0.2 vs 0.4; P < .01) but higher rates of hypercholesterolemia (10% vs 1%; P = .01) than youth wit

47 The most common long-term events were hypercholesterolemia (31%) and osteoporosis (19%).

48 al cohort, 184 of 214 patients with familial hypercholesterolemia (86%) and 77 of 95 siblings (81%) w

49 4]) among 17,728 unique subjects with severe hypercholesterolemia (920 patients with FH) on the basis

50 % confidence interval: 1-3; P=0.05), 2.9 for hypercholesterolemia (95% confidence interval: 1-5; P=0.

51 Hypercholesterolemia, a common comorbidity of obesity, h

52 wine model of ischemia-reperfusion (IR) that hypercholesterolemia abolishes HDL-related cardioprotect

53 and reconstitution capacity of HSCs and that hypercholesterolemia accelerates HSC aging phenotypes by

54 Hypercholesterolemia accelerates the phenotypes of aging

55 Hypercholesterolemia acts in platelets and hematopoietic

56 Hypercholesterolemia acts synergistically with LNK defic

57 et production and activity in the setting of hypercholesterolemia, amenable to pharmaceutical interve

58 cluding diabetes mellitus, hypertension, and hypercholesterolemia among 69 505 US women in the Nurses

59 0.0056 mm per year in patients with familial hypercholesterolemia and 0.0057 mm per year in siblings

60 , Pod-ATTAC mice and NTS-treated mice showed hypercholesterolemia and a 7- to 24-fold induction in pl

61 l protective effect of higher iron status on hypercholesterolemia and a detrimental role on risk of s

62 ed FXR-FGF15 signaling may be potential anti-hypercholesterolemia and anti-hyperlipidemia therapies.

63 Statins are a class of drugs used to treat hypercholesterolemia and are frequently used in the elde

64 hermore, miR-30c mimic significantly reduced hypercholesterolemia and atherosclerosis in Apoe(-/-) mi

65 ntrast, BAFF overexpression markedly reduced hypercholesterolemia and atherosclerosis in hyperlipidem

66 r apoE4 in VMCs was sufficient to rescue the hypercholesterolemia and atherosclerosis phenotypes seen

67 olesterol diet for 16 weeks to induce severe hypercholesterolemia and atherosclerosis progression.

68 ghts into identifying therapeutic targets of hypercholesterolemia and atherosclerosis with rabbit mod

69 on of Ldlr with AAV-CRISPR results in severe hypercholesterolemia and atherosclerosis.

70 (Ldlr), which when deleted, leads to severe hypercholesterolemia and atherosclerosis.

71 ls is a viable treatment option for reducing hypercholesterolemia and atherosclerosis.

72 animal for studying human diseases, such as hypercholesterolemia and atherosclerosis.

73 nd control of inflammation in the context of hypercholesterolemia and atherosclerosis.

74 esent potential targets for the treatment of hypercholesterolemia and atherosclerosis.

75 drugs for old patients with hyperlipidemia, hypercholesterolemia and atherosclerotic diseases by red

76 validated therapeutic approach for fighting hypercholesterolemia and cardiovascular diseases.

77 These animals have retinal hypercholesterolemia and convert excess retinal choleste

78 ically validated target for the treatment of hypercholesterolemia and coronary artery disease.

79 Her medical history was positive for hypercholesterolemia and depression.

80 riate models that adjusted for hypertension, hypercholesterolemia and diabetes (OR 1.31, 95% CI 0.98-

81 ART use was independently associated with hypercholesterolemia and dysglycemia.

82 in use for confirmatory testing of familial hypercholesterolemia and for cascade screening of relati

83 Individuals with hypercholesterolemia and hypertension who fail to take t

84 We evaluated the impact of polygenic hypercholesterolemia and hypertriglyceridemia to lipid l

85 Both groups had similar proportions of hypercholesterolemia and hypertriglyceridemia.

86 e of monogenic mutations related to familial hypercholesterolemia and of high polygenic score (cumula

87 FDA for the treatment of homozygous familial hypercholesterolemia and over 35 second generation PS AS

88 as drugs (e.g., to treat homozygous familial hypercholesterolemia and spinal muscular atrophy) or as

89 ed with enhanced macrophage inflammation and hypercholesterolemia and that macrophage alpha1AMPK may

90 ified self-antigens generated in response to hypercholesterolemia and that presentation of such antig

91 insights into the retinal response to local hypercholesterolemia and the retinal significance of cho

92 of a 3-year-old boy with homozygous familial hypercholesterolemia and unstable coronary artery diseas

93 ving positive screening results for familial hypercholesterolemia and were consequently at high risk

94 were 20.1% (with hypertension) and 17% (with hypercholesterolemia) and 24.5% in the group without dia

95 cused on screening for heterozygous familial hypercholesterolemia, and 1 review focused on screening

96 , but it is associated with atherosclerosis, hypercholesterolemia, and abnormal transforming growth f

97 in the LDL receptor (LDLR) leading to severe hypercholesterolemia, and associated with an increased r

98 tors, including hypertension, hyperglycemia, hypercholesterolemia, and high circulating levels of tri

99 associated with progressive hypercholanemia, hypercholesterolemia, and hypertriglyceridemia, which ca

100 aging, common conditions such as diabetes or hypercholesterolemia, and with certain genetic disorders

101 s for testing of total serum cholesterol for hypercholesterolemia are appropriate and are well-adhere

102 s, and inverse associations with obesity and hypercholesterolemia are described.

103 ediatric patients with heterozygous familial hypercholesterolemia are not known.

104 ations for risk assessment, hypertension and hypercholesterolemia are not reviewed.

105 intracranial stenosis while hypertension and hypercholesterolemia are the major risk factors of extra

106 diabetes, prehypertension, hypertension, and hypercholesterolemia) as well as presence of the APOE ep

107 sults argue for the apoE deficiency, and not hypercholesterolemia, as the cause for the increased sev

108 notransferases and alkaline phosphatase, and hypercholesterolemia, as well as low serum ceruloplasmin

109 While monogenic familial hypercholesterolemia associates with severely increased

110 Risk factors for hypercholesterolemia at 1 year were patient age (OR, 1.1

111 ries of heterozygous and homozygous familial hypercholesterolemia, based on clinical criteria with an

112 to adipocyte hypertrophy as well as systemic hypercholesterolemia, body fat accumulation, and glucose

113 definitive treatment of homozygous familial hypercholesterolemia but died of noncardiac complication

114 ith sex, diabetes, systemic hypertension, or hypercholesterolemia but was associated with history of

115 e likely to be obese, hypertensive, and have hypercholesterolemia, but were less likely to be prescri

116 Establishment of familial hypercholesterolemia cascade testing programs in the US

117 New case detection in familial hypercholesterolemia cascade testing programs tended to

118 luding age, diabetes mellitus, hypertension, hypercholesterolemia, chronic kidney disease, smoking, a

119 The SAFEHEART study (Spanish Familial Hypercholesterolemia Cohort Study) is a large, ongoing r

120 use the SAFEHEART registry (Spanish Familial Hypercholesterolemia Cohort Study) to define key risk fa

121 ases enrolled in SAFEHEART (Spanish Familial Hypercholesterolemia Cohort Study) were tested for genet

122 subjects with IHD, premature IHD, and severe hypercholesterolemia compared with those in the general

123 tic patients with he-FH and 131 non-familial hypercholesterolemia controls underwent CT computed tomo

124 pact of the founder French-Canadian familial hypercholesterolemia deletion ( LDLR delta >15 kb deleti

125 ance of genetic analysis to improve familial hypercholesterolemia diagnosis accuracy.

126 obesity, hypertension, heart conditions, or hypercholesterolemia differed between older and younger

127 We found that hypercholesterolemia downregulates Ten eleven translocat

128 ssments to identify elevated blood pressure, hypercholesterolemia, dysglycemia, renal insufficiency,

129 s adjusted for alcohol use, anticoagulation, hypercholesterolemia, education, and medical insurance s

130 METHODS AND We observed that hypercholesterolemia elevated the intrahepatic regulator

131 l involving pediatric patients with familial hypercholesterolemia, evolocumab reduced the LDL cholest

132 cium score, diabetes mellitus, hypertension, hypercholesterolemia, family history of coronary artery

133 arent xanthomas in 24 patients with familial hypercholesterolemia (FH) (six men, 18 women; mean age +

134 Heterozygous familial hypercholesterolemia (FH) affects up to 1 in 200 individ

135 on the prevalence and treatment of familial hypercholesterolemia (FH) among U.S. adults who experien

136 ion PCSK9 mutations associated with familial hypercholesterolemia (FH) and clustered at the predicted

137 Patients with heterozygous familial hypercholesterolemia (FH) and coronary heart disease hav

138 Familial hypercholesterolemia (FH) and elevated lipoprotein(a) [L

139 ere, we found that individuals with familial hypercholesterolemia (FH) had significantly higher ONE-k

140 c cardiovascular disease (ASCVD) in familial hypercholesterolemia (FH) have been described, models fo

141 Patients with familial hypercholesterolemia (FH) have elevated lipoprotein(a);

142 Humans with familial hypercholesterolemia (FH) have increased lipoprotein dic

143 Despite the greater prevalence of familial hypercholesterolemia (FH) in subjects with ischemic hear

144 atment patterns among patients with familial hypercholesterolemia (FH) in the United States remain po

145 Familial hypercholesterolemia (FH) is a common autosomal codomina

146 Familial hypercholesterolemia (FH) is an autosomal dominant disor

147 Familial hypercholesterolemia (FH) is an inherited disease of lip

148 Familial hypercholesterolemia (FH) is characterized by elevated c

149 Familial hypercholesterolemia (FH) is characterized by severely e

150 The prevalence of familial hypercholesterolemia (FH) is commonly reported as 1 in 5

151 Familial hypercholesterolemia (FH) is the most common genetic dis

152 protein cholesterol in heterozygous familial hypercholesterolemia (FH) or atherosclerotic cardiovascu

153 Familial hypercholesterolemia (FH) remains underdiagnosed despite

154 e was recently addressed in a large familial hypercholesterolemia (FH) screening study, which reporte

155 treatment option for patients with familial hypercholesterolemia (FH) who are unable to reach low-de

156 cer (HBOC), Lynch syndrome (LS) and familial hypercholesterolemia (FH)-have been termed the Centers f

157 patients with clinically-diagnosed familial hypercholesterolemia (FH).

158 lts in identifying individuals with familial hypercholesterolemia (FH).

159 ified in patients with heterozygous familial hypercholesterolemia (FH).

160 ian diseases affecting cholesterol: familial hypercholesterolemia (FH; LDLR and APOB) and familial hy

161 the podocytes of the kidney produces severe hypercholesterolemia for which novel treatments are urge

162 A total of 214 patients with familial hypercholesterolemia (genetically confirmed in 98% of th

163 ith GBM who had a prior history of asthma or hypercholesterolemia had significantly higher relative r

164 Child-parent screening for familial hypercholesterolemia has been proposed to identify perso

165 Heterozygous familial hypercholesterolemia (HeFH) is an autosomal dominant dis

166 ease in tier 1 genomic conditions - familial hypercholesterolemia, hereditary breast and ovarian canc

167 emical mediator of the metastatic effects of hypercholesterolemia.High cholesterol is a risk factor f

168 sex, age, current smoking status, history of hypercholesterolemia, history of diabetes, aspirin use,

169 ike cells generated from homozygous familial hypercholesterolemia (hoFH) iPSCs to identify drugs that

170 Homozygous familial hypercholesterolemia (HoFH) is a rare disease characteri

171 Homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder, is

172 index, physical activity, smoking, diabetes, hypercholesterolemia, hormone therapy, and alcohol, caff

173 fidence Interval [CI]: 1.24-5.58; p = 0.01), hypercholesterolemia (HR: 1.95; 95% CI: 1.09-3.50; p = 0

174 (HR: 2.22; 95% CI: 1.02-4.83; p = 0.04) and hypercholesterolemia (HR: 1.99; 95% CI: 1.11-3.56; p = 0

175 ren and Adolescents With Homozygous Familial Hypercholesterolemia [HYDRA]; NCT02226198).

176 e interval [CI] 0.64-0.81, P = 4 x 10-8) and hypercholesterolemia (hypercholesterolemia: OR 0.88, 95%

177 o the treatment of established risk factors (hypercholesterolemia, hypertension, and diabetes mellitu

178 ble for overweight (but not morbidly obese), hypercholesterolemia, hypertension, cataract surgeries,

179 ablished cardiovascular risk factors such as hypercholesterolemia, hypertension, diabetes mellitus, a

180 ary lifestyle) and three major risk factors (hypercholesterolemia, hypertension, diabetes).

181 hy were evaluated: diabetes, hypothyroidism, hypercholesterolemia, hypertension, varicella zoster, pe

182 ave a positive screening result for familial hypercholesterolemia if he or she had the same mutation

183 have positive screening results for familial hypercholesterolemia if their cholesterol level was elev

184 nds of concurrent diabetes, hypertension and hypercholesterolemia in 36,673 subjects were obtained fr

185 c mimic to the liver diminished diet-induced hypercholesterolemia in C57BL/6J mice.

186 l molecular diagnoses performed for familial hypercholesterolemia in Spain between 1996 and 2015 (n=1

187 s) are set to revolutionize the treatment of hypercholesterolemia in the management of atheroscleroti

188 oE-deficient (apoE(-/-)) mice and found that hypercholesterolemia in these mice was associated with a

189 revents hepatic cholesterol accumulation and hypercholesterolemia in Western diet-fed mice.

190 The diabetes with concurrent hypertension or hypercholesterolemia incidences also increased significa

191 nce of concurrent diabetes, hypertension and hypercholesterolemia increased from 3% in 1999-2000 to 6

192 In this study, we show that hypercholesterolemia increases the incidence and patholo

193 There is evidence that hypercholesterolemia increases the risk of atheroscleros

194 factor (diabetes mellitus, hypertension, or hypercholesterolemia) independently increased CHD risk (

195 isability, especially for high-risk familial hypercholesterolemia individuals.

196 Hypercholesterolemia induced an important change in HDL-

197 Hypercholesterolemia induced larger HDL particles.

198 Moreover, hypercholesterolemia induced the differentiation of intr

199 oss of Notch1 in adult endothelium increases hypercholesterolemia-induced atherosclerosis in the desc

200 direct effect on the natural development of hypercholesterolemia-induced atherosclerosis, but may pl

201 Srebp2 inhibition impairs hypercholesterolemia-induced HSPC expansion.

202 We demonstrate that hypercholesterolemia induces HDL lipidomic changes, losi

203 Statins, widely used to treat hypercholesterolemia, inhibit the 3-hydroxy-3-methylglut

204 vascular dendritic cells (DCs) that, during hypercholesterolemia, initiate atherosclerosis by being

205 The prevalence of familial hypercholesterolemia is 1 in 250, but <10% of patients a

206 Hypercholesterolemia is a key risk factor for atheroscle

207 oints, control of diabetes, hypertension and hypercholesterolemia is a necessity as those risk factor

208 Hypercholesterolemia is a risk factor for atherothrombot

209 Hypercholesterolemia is a well known risk factor for the

210 Hypercholesterolemia is associated with cognitively dete

211 Familial hypercholesterolemia is characterized by an elevated lev

212 Familial hypercholesterolemia is characterized by impaired uptake

213 Homozygous familial hypercholesterolemia is characterized by premature cardi

214 Familial hypercholesterolemia is characterized by severely elevat

215 ynthesis inhibitors widely used for treating hypercholesterolemia, is associated with improved diseas

216 The first, familial hypercholesterolemia, is the clearest case for utility o

217 Persistent hypercholesterolemia leads to immune responses against l

218 nd hyperlipidemia and patients with familial hypercholesterolemia less frequently develop diabetes, t

219 art disease (IHD), premature IHD, and severe hypercholesterolemia (low-density lipoprotein >=190 mg/d

220 ons, such as diabetes mellitus, obesity, and hypercholesterolemia making surgical intervention more d

221 evolocumab 420 mg with placebo in PLHIV with hypercholesterolemia/mixed dyslipidemia taking maximally

222 en, including 32 children who had a familial hypercholesterolemia mutation and 8 who did not have the

223 ], 0.2 to 0.4), including 20 with a familial hypercholesterolemia mutation and 8 with a repeat choles

224 was elevated and they had either a familial hypercholesterolemia mutation or a repeat elevated chole

225 A familial hypercholesterolemia mutation was present in 36 of these

226 terol was 206 mg/dL in those with a familial hypercholesterolemia mutation, 132 mg/dL in those with h

227 el of less than 1.53 MoM also had a familial hypercholesterolemia mutation.

228 Both familial hypercholesterolemia mutations and high polygenic score

229 cholesterol levels and to test for familial hypercholesterolemia mutations in 10,095 children 1 to 2

230 riousness and nondeleteriousness of familial hypercholesterolemia mutations were based on literature

231 n to confer similar risk to that of familial hypercholesterolemia mutations.

232 ng pregnancy include hypertensive disorders, hypercholesterolemia, myocardial infarction, cardiomyopa

233 with PUFAs in healthy subjects with moderate hypercholesterolemia (n = 99).

234 ficantly more common, including sleep apnea, hypercholesterolemia, obesity, indicators of past or cur

235 Hypercholesterolemia (odds ratio [OR]: 1.27; 95% CI: 1.2

236 we tested the role of PCSK9 in mediating the hypercholesterolemia of nephrotic syndrome.

237 However, the effect of hypercholesterolemia on hepatic T-cell differentiation r

238 However, the mechanism by which hypercholesterolemia or any metabolic disorder increases

239 ss of medications for patients with familial hypercholesterolemia or clinical atherosclerotic cardiov

240 , cardiovascular risk factors (hypertension, hypercholesterolemia or diabetes mellitus), cardiovascul

241 p in children because of homozygous familial hypercholesterolemia or other underlying conditions.

242 d are clinically prescribed to patients with hypercholesterolemia or related cardiovascular condition

243 ardiovascular disease, heterozygous familial hypercholesterolemia, or both met randomization criteria

244 ardiovascular disease, heterozygous familial hypercholesterolemia, or both.

245 n acquired pathologies, such as diabetes and hypercholesterolemia, or can result from genetic disorde

246 .81, P = 4 x 10-8) and hypercholesterolemia (hypercholesterolemia: OR 0.88, 95% CI 0.83-0.93, P = 2 x

247 0.0001), arterial hypertension (P < 0.0001), hypercholesterolemia (P = 0.0005), history of smoking (P

248 0.008), hypertriglyceridemia (p = 0.040) and hypercholesterolemia (p = 0.036); GGC with lower risk of

249 taract (P=0.003), hypertension (P=0.02), and hypercholesterolemia (P<0.001) were all significantly hi

250 nce of type 2 diabetes was 1.75% in familial hypercholesterolemia patients (n = 440/25,137) vs 2.93%

251 Of the 58,266 hypercholesterolemia patients age 30+ years without pre-

252 In hypercholesterolemia patients with hypertension, relativ

253 In all hypercholesterolemia patients, the adjusted odds ratio f

254 ndocrine treatment on cholesterol levels and hypercholesterolemia per se may counteract the intended

255 cholesterol efflux capacity in the familial hypercholesterolemia plasma.

256 Hypercholesterolemia-prone mice that were engrafted with

257 Hypercholesterolemia protects against ventricular fibril

258 AP-1B and its coadaptor, autosomal recessive hypercholesterolemia protein (ARH), for sorting to the b

259 In patients with homozygous familial hypercholesterolemia receiving maximum doses of lipid-lo

260 more frequently women, with higher rates of hypercholesterolemia, renal impairment, diabetes, and mu

261 justing for age, sex, BMIZ, elevated BP, and hypercholesterolemia (RR, 1.43; P = .02).

262 y during childhood in patients with familial hypercholesterolemia slowed the progression of carotid i

263 RF profile (hypertension, diabetes mellitus, hypercholesterolemia, smoking, physical activity, and ob

264 In a mouse model combining hyperglycemia and hypercholesterolemia (streptozotocin diabetic, apoE-defi

265 e was lower among the patients with familial hypercholesterolemia than among their affected parents (

266 ts with concomitant type 2 diabetes had more hypercholesterolemia than the other groups (8 % vs 6 % a

267 vivo, m-RCT was evaluated in mouse models of hypercholesterolemia that were naturally deficient in CE

268 VD risk factors (diabetes, hypertension, and hypercholesterolemia) that could be attributed to poor a

269 ic heart disease, myocardial infarction, and hypercholesterolemia) that were associated with genetica

270 Hypercholesterolemia, the driving force of atheroscleros

271 In addition to hypercholesterolemia, the proinflammatory Paigen diet si

272 In patients with refractory hypercholesterolemia, the use of evinacumab significantl

273 After months of hypercholesterolemia, their presence in plaques is overt

274 Among adults with heterozygous familial hypercholesterolemia, those who received inclisiran had

275 io, 482 adults who had heterozygous familial hypercholesterolemia to receive subcutaneous injections

276 f PCSK9, a target for clinical management of hypercholesterolemia, to demonstrate this concept.

277 egies, such as treatment of hypertension and hypercholesterolemia, to reduce risk in appropriately se

278 term effects of evolocumab during open-label hypercholesterolemia treatment for up to 5 years.

279 Simvastatin, an agent for hypercholesterolemia treatment, activated the MCM7/p-RB/

280 elopment of postpartum chronic hypertension, hypercholesterolemia, type 2 diabetes mellitus, and chan

281 y plasma derived from subjects with familial hypercholesterolemia was assessed.

282 lar disease among the patients with familial hypercholesterolemia was compared with that among their

283 ith a positive screening result for familial hypercholesterolemia was considered to have a positive s

284 ximum prevalence of hypertriglyceridemia and hypercholesterolemia was found on postoperative day 10 a

285 12 common alleles associated with polygenic hypercholesterolemia was performed in 103 patients with

286 he occurrence of concurrent hypertension and hypercholesterolemia was stable over the study period.

287 s, connective tissue disorders, and familial hypercholesterolemia were identified.

288 ments for concurrent diabetes, hypertension, hypercholesterolemia were improved from 69.8% in 1999-20

289 HBP and hypercholesterolemia were the most prevalent comorbiditi

290 conditions, including diabetes mellitus and hypercholesterolemia, which are risk factors for stroke.

291 ish language of cascade testing for familial hypercholesterolemia, which reported the number of index

292 in long-term studies involving patients with hypercholesterolemia who are receiving guideline-recomme

293 tients with or without heterozygous familial hypercholesterolemia who had refractory hypercholesterol

294 1 ratio 65 patients with homozygous familial hypercholesterolemia who were receiving stable lipid-low

295 Patients with refractory hypercholesterolemia, who have high low-density lipoprot

296 The molecular determinants connecting hypercholesterolemia with hematopoiesis are unclear.

297 a new diagnosis of cirrhosis, we associated hypercholesterolemia with well-preserved hepatic functio

298 lial hypercholesterolemia who had refractory hypercholesterolemia, with a screening LDL cholesterol l

299 At baseline, older age, hypercholesterolemia, worse visual acuity, larger choroi

300 omeostasis, we are wondering if diet induced hypercholesterolemia would influence the susceptibility